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Abstract
Adjuvants potentiate antigen-specific protective immune responses and can be key elements promoting vaccine
effectiveness. We previously reported that the Onchocerca volvulus recombinant protein rOv-ASP-1 can induce activation
and maturation of naı ¨ve human DCs and therefore could be used as an innate adjuvant to promote balanced Th1 and Th2
responses to bystander vaccine antigens in mice. With a few vaccine antigens, it also promoted a Th1-biased response
based on pronounced induction of Th1-associated IgG2a and IgG2b antibody responses and the upregulated production of
Th1 cytokines, including IL-2, IFN-c, TNF-a and IL-6. However, because it is a protein, the rOv-ASP-1 adjuvant may also
induce anti-self-antibodies. Therefore, it was important to verify that the host responses to self will not affect the
adjuvanticity of rOv-ASP-1 when it is used in subsequent vaccinations with the same or different vaccine antigens. In this
study, we have established rOv-ASP-1’s adjuvanticity in mice during the course of two sequential vaccinations using two
vaccine model systems: the receptor-binding domain (RBD) of SARS-CoV spike protein and a commercial influenza virus
hemagglutinin (HA) vaccine comprised of three virus strains. Moreover, the adjuvanticity of rOv-ASP-1 was retained with an
efficacy similar to that obtained when it was used for a first vaccination, even though a high level of anti-rOv-ASP-1
antibodies was present in the sera of mice before the administration of the second vaccine. To further demonstrate its utility
as an adjuvant for human use, we also immunized non-human primates (NHPs) with RBD plus rOv-ASP-1 and showed that
rOv-ASP-1 could induce high titres of functional and protective anti-RBD antibody responses in NHPs. Notably, the rOv-ASP-
1 adjuvant did not induce high titer antibodies against self in NHPs. Thus, the present study provided a sound scientific
foundation for future strategies in the development of this novel protein adjuvant.
Citation: Wang J, Tricoche N, Du L, Hunter M, Zhan B, et al. (2012) The Adjuvanticity of an O. volvulus-Derived rOv-ASP-1 Protein in Mice Using Sequential
Vaccinations and in Non-Human Primates. PLoS ONE 7(5): e37019. doi:10.1371/journal.pone.0037019
Editor: Kevin K. A. Tetteh, London School of Hygiene and Tropical Medicine, United Kingdom
Received November 18, 2011; Accepted April 12, 2012; Published May 17, 2012
Copyright:  2012 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the VP fund for New Initiatives (Mohandas Narla), New York Blood Center, and by the National Center for Research
Resources and the Office of Research Infrastructure Programs (ORIP) of the National Institutes of Health through Grant Number P51 RR00164-50. It was also
supported by a grant from the National Institutes of Health (R01 AI068002) to SJ. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: Dynavax Technologies Corporation donated the CpG-C
ISSODN C274 adjuvant used in the NHP experiment. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: slustigman@nybloodcenter.org.
Introduction
The use of an adjuvant is a key element in promoting vaccine
effectiveness because it can stimulate the immune system and
accelerate, prolong, or enhance antigen-specific immune respons-
es, even when used in combination with weak vaccine antigens [1].
Adjuvants have been used in vaccines since the early 20th Century
following more than 100 years of research. In the U.S., Alum
remains the sole FDA-approved adjuvant for general use of
vaccines [2]. However, few adjuvants have been licensed for use
around the world [3]. No new adjuvants have been approved in
the United States since the 1930s, and only recently has the
European Heads of Medicines Agencies licensed the MF59, AS03
and AS04 adjuvants for use with the FluadH, Fendrix
TM and
Cervarix
TM defined vaccines, respectively [4]. Cervarix
TM which
uses AS04, a combination of aluminum hydroxide and monopho-
sphoryl lipid A (MPL), in its formulation was also licensed by FDA
on October 16, 2009, to prevent cervical cancer caused by human
papillomavirus types 16 and 18. Adjuvants are important in
guiding the type of adaptive response that is induced after
vaccination and that is most effective against incoming infections.
The development of novel adjuvants that stimulate discrete subsets
of immune cells, in particular, cytotoxic T-lymphocytes (CTL), is
required to unleash the full potential of new vaccines and
immunotherapy strategies [5]. Although tremendous progress
has been made in the development of many vaccine platforms,
including DNA-based vaccines, recombinant subunit vaccines,
viruses and conjugates, the absence of safe and effective adjuvants
impedes the clinical development of such new generations of
vaccines. Interest in developing new adjuvants has increased
significantly over the past decade, as highlighted by the following
issues [6,7]: 1) the inability of traditional approaches to develop
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HCV; 2) the emergence of epidemics or outbreaks of new
infectious diseases with high mortality, especially those causing
serious threats to public health and socioeconomic stability
worldwide (e.g., SARS, Ebola, West Nile, Dengue, pandemic flu
and nvCJD); 3) the re-emergence of ‘‘old’’ infections like
tuberculosis; 4) the continuing spread of antibiotic-resistant
bacteria; and 5) the increased threat of bioterrorism. Therefore,
the molecular design of potently adjuvanted vaccines that would
enhance antigen uptake in vivo and potentially also simplify their
adjuvant requirements would be highly desirable [8].
There are many reports showing that helminth-derived
molecules have potent regulatory or stimulatory effects on the
immune system of their mammalian hosts (reviewed in [9], [10–
21]). Some of these molecules were shown to contain pathogen
associated molecular pattern that bind to endocytic-pattern
recognition receptors on antigen presenting cells (APCs). Three
helminth products have also been reported to act as adjuvants in
experimental vaccine models. Proteins secreted by adult Nippo-
strongylus brasiliensis (NES) induced strong Th2 responses in mice
immunized with hen egg lysozyme [22]. NES actively matured
dendritic cells (DC) and selectively up-regulated CD86 and
OX40L, together with IL-6 production, while blocking IL-12p70
responsiveness in a manner consistent with Th2 generation in vivo
[23]. Similarly, lacto-N-fucopentaose III (LNFPIII), a carbohy-
drate found on the surface of the eggs of a human parasite,
Schistosoma mansoni, acted as a Th2 adjuvant for human serum
albumin when injected intranasally, subcutaneously or intraper-
itonealy into mice [24]. It functions as an innate Th2 promoter via
its action on murine DCs. Its ability to drive DC2 maturation was
shown to be dependent on signaling via toll-like receptor 4 (TLR4)
[25]. Finally, when co-administered with an inactivated anti-
influenza vaccine in both young and aged mice, a 19 aa synthetic
peptide (GK-1) from Taenia crassiceps cysticerci has induced
increased levels of anti-influenza antibodies in aged mice, both
before and after infection, reduced the local inflammation that
accompanied influenza vaccination itself, and favored virus
clearance after infection in both young and aged mice [26].
A recombinant Onchocerca volvulus activation-associated protein-
1, rOv-ASP-1, has been shown to be a novel protein adjuvant that
can increase specific immune responses in mice, both humoral and
cellular responses, against recombinant protein or peptide-based
Figure 1. Anti-RBD antibody responses in vaccinated mice. RBD-specific responses in mice immunized with recombinant SARS-CoV RBD in
the presence of the rOv-ASP-1, Alum or CpG. Titer of RBD- specific IgG and IgG subtypes was detected by ELISA using sera from mice before (pre-
immune) and 10 days after each vaccination. * indicates significant difference (p,0.05) among multiple comparisons; in particular between mice that
were immunized in the presence of rOv-ASP-1 or control adjuvants vs. no adjuvant.
doi:10.1371/journal.pone.0037019.g001
Adjuvanticity of rOv-ASP-1 in Mice and in NHPs
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37019antigens when formulated in aqueous mixtures [14,27,28,29]. We
have previously suggested that these effects are probably attained
through the cellular activation of APCs such as dendritic cells via
TLR-2 and TLR-4 [27]. The rOv-ASP-1 adjuvant is able to induce
balanced Th2 and Th1-associated IgG1 and IgG2a antibodies to
proteins, polypeptides and small peptides. With a few antigens
such as rgp41, RBD and HBsAg, it also promoted a putative Th1-
biased response based on pronounced induction of Th1-associated
IgG2a and IgG2b antibody responses and/or a significantly
upregulated production of Th1 cytokines, including IL-2, IFN-c,
TNF-a, and IL-6 [14,27,29,30] . Its ability to augment Th1-
associated antibody responses was further demonstrated in studies
using three commercial inactivated vaccines against hemorrhagic
fever with renal syndrome, flu and Rabies [29]. Moreover, in a
novel recombinant configuration, rOv-ASP-1 fused to 3 copies of
the highly conserved extracellular domain of the H5N1 influenza
M2 protein sequence was able to induce high levels of M2e-
specific IgG, IgG1, IgG2a providing strong cross-protection from
a lethal challenge with 3LD50 or 10 LD50 of H5N1 viruses of
different clades (clade 1: VN/1194, or clade 2.3.4: SZ/406H [28].
In this study, we further demonstrated the adjuvanticity of rOv-
ASP-1 in sequential vaccines in mice and also confirmed its ability
to be a potent innate adjuvant in NHPs.
Results
The rOv-ASP-1 adjuvant enhances humoral and cellular
responses after immunization with rRBD of SARS-CoV in
mice
To evaluate the adjuvant activity of rOv-ASP-1, mice were
immunized with SARS-CoV rRBD in the presence or absence of
rOv-ASP-1 or with Alum or CpG for comparison. We previously
reported that rOv-ASP-1 could effectively induce a mixed, but
Th1-skewed immune response against rS and rRBD in immunized
mice [27]. As shown in Figure 1, the titers of RBD-specific IgG,
IgG1, IgG2a and IgG2b antibodies increase after the first or
second boost immunization in the sera of mice immunized with
rRBD plus rOv-ASP-1, which were all significantly higher than in
mice immunized with rRBD alone. The IgG and IgG2a responses
in mice vaccinated with rRBD in the presence of Alum were
significantly higher only after the second boost; only the IgG1
response was significantly higher after the first boost. The anti-
rRBD IgG response was significantly higher in the presence of
CpG only after the second boost when compared to mice
vaccinated only with rRBD (1:102,400 vs. 1:11,314). Notably,
the rOv-ASP-1 augmented IgG antibody response to rRBD was
almost 4 times higher than the Alum vaccination group (64,000 vs.
16,000) and 5.7 times higher than the CpG vaccination group
(64,000 vs. 11,200) already after the first boost. Further
comparison of the rOv-ASP-1 and the Alum induced rRBD
antibody responses after the second boost revealed similar levels of
IgG1 (1,884,544 vs. 1,722,156); two-fold higher level of IgG2a
(935,763 vs. 512,000) as well as ten times higher level of IgG2b
(430,538 vs. 45,255) endpoint titers in the rOv-ASP-1 vaccine
group. Comparison of the rOv-ASP-1 and the CpG induced rRBD
antibody responses after the second boost revealed a 27 fold
increase in IgG1 (1,884,544 vs. 68,000), 14.6 fold increase in
IgG2a (935,763 vs. 64,000), and 215 fold increase in IgG2b
(430,538 vs. 2,000) endpoint titers. Each adjuvant/rRBD model
performed differently depending on the adjuvant, e.g., a skewed
Th2 response with Alum (IgG1/IgG2a=3.3), but a mixed Th1/
Th2 response with CpG (IgG2a/IgG1=0.94) and rOv-ASP-
1(IgG2a/IgG1=2), with a predominance of Th1-associated
antibodies (when both IgG2a and IgG2b are taken into account)
with rOv-ASP-1. These results further supported our previous
studies showing that rOv-ASP-1 can induce a more balanced
Figure 2. Neutralizing antibody titers induced in vaccinated
mice. Neutralization of SARS pseudovirus infection by mouse antisera
from each rRBD immunization group 10 days after second boost.
Infection of 293T/ACE2 cells by SARS pseudovirus was determined in
the presence of antisera at a series of 2-fold dilutions, and 50%
neutralization titer (NT50) was calculated for each sample. * indicates
significant difference (p,0.05).
doi:10.1371/journal.pone.0037019.g002
Table 1. Cytokine responses to rRBD and its CD4
+ and CD8
+
epitopes in vaccinated mice.
Cytokine(pg/ml) Vaccine Groups
RBD+PBS
RBD+rOv-
ASP-1 RBD+Alum RBD+CPG
Responses to rRBD
IL-2 33661 7 3 681 2 9 613 1765
IL-6 20612 61612 107611 3166
IL-10 962 1,175691 1,8586137 220645
IFN-c 20615 9 4 626 5 9 6216 881660
TNF-a 31681 6 5 615 141637 86675
IL-17A 8632 7 617 9 624 168695
Responses to N50 (CD8
+ epitope)
IL-2 22641 6 4 615 177623 36626
IL-6 5615 5 610 79620 60
IL-10 3615 4 5 6221 929663 0 67
IFN-c 3604 2 8 625 550617 2906176
TNF-a 14611 0 2 641 2 0 613 40649
IL-17A 4612 9 622 19615 67
Responses to N60 (CD4
+ epitope)
IL-2 36661 6 5 631 183612 48624
IL-6 15637 0 648 8 615 1863
IL-10 6638 8 7 6337 1,076663 6761
IFN-c 3617 2 6 6139 505681 7 0 628
TNF-a 14601 1 1 614 138622 7 626
IL-17A 7612 8 664 3 633 20619
doi:10.1371/journal.pone.0037019.t001
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associated antibody response than other adjuvants used with the
same bystander antigen such as Alum or CpG (this study) or the
MLP plus TDM adjuvant [14,27,29].
To further evaluate whether the induced IgG antibodies could
neutralize infection of SARS-CoV in vitro (Fig. 2), we tested the
antisera from the 10-day post-second boost immunization and
found that mice immunized with rRBD in the presence of rOv-
ASP-1 contained a very high titer of neutralizing antibodies
against infection by SARS-CoV pseudovirus (NT50=1:76,592),
which was not significantly different than in neutralizing
antibodies found in sera from mice immunized with rRBD plus
the Alum adjuvant (NT50=1:64,666).
The subclass of immunoglobulin induced after immunization is
an indirect measure of the relative contribution of Th1-type
cytokines vs.Th2-type cytokines. In this study, the data from the
CBA analyses showed that the levels of Th1- and Th2-type
cytokine secretion were significantly higher in mice immunized
with rRBD+rOv-ASP-1 or Alum than in those who were
immunized with rRBD alone (Table 1). The rOv-ASP-1 induced
the production of Type I proinflammatory cytokines (IL-2, IFN-c,
TNF-a, IL-17A and IL-6) to the same extent as Alum, as well as
the Th2/regulatory cytokines IL-6 and IL-10. There was no
significant recall induction of the Th2 IL-4 or IL-5 cytokines by
rRBD (data not shown). Notably, the responses to rRBD when
formulated with CpG are in comparison more IFN-c and IL-17A
dominant with diminished IL-2, TNF-a, IL-10 and IL-6
responses. We found that the variation between individual mice
was very low [31,32], and therefore we are confident that the
results obtained using the pooled spleens are a good representation
of what would have been the outcome if we had used individual
mice.
Distinct from the previous studies are the responses to two
RBD-specific peptides; N50 (CD8
+ T cell epitope) and N60 (CD4
+
T cell epitope) (Table 1). Interestingly, the cytokine levels in the
culture supernatants of the murine splenocytes when stimulated
with either N50 or N60 were similar to those produced by
stimulation with the full length rRBD in mice vaccinated with
rRBD+rOv-ASP-1, thus further confirming the ability of rOv-ASP-
1 to elicit RBD-specific CD8
+ and CD4
+ cellular responses in the
tested vaccine formulation.
The rOv-ASP-1 adjuvant enhances immune responses in
a sequential influenza vaccine
Using a mouse model in which we first immunized mice with
rRBD of SARS-CoV, we evaluated the efficacy of rOv-ASP-1
adjuvanticity in a sequential vaccination in which we used the HAs
of three influenza viruses (A/Brisbane/59/2007, IVR-148
(H1N1); A/Uruguay/716/2007, NYMC X-175C (H3N2) (an
A/Brisbane/10/2007-like virus); and B/Brishbane/60/2008) as
the model antigens. Naı ¨ve BALB/c mice or mice ten weeks after
immunization with rRBD in the presence of rOv-ASP-1 were
immunized with HAs of influenza viruses in the absence or
presence of yeast expressed rOv-ASP-1 (100 mg/mice). The mice
that were previously immunized with rRBD in the presence of rOv-
ASP-1 had endpoint total anti-rOv-ASP-1 antibody titers of
1:256,000–1:512,000 at the time of the priming with the second
vaccine. As shown in Table 2, similar IgG1 and IgG2a humoral
immune responses against the influenza viruses were induced in
the mice vaccinated previously with rRBD plus rOv-ASP-1
adjuvant and those administered with PBS only. Moreover, the
IgG2b was higher in the group that got the sequential vaccine
(162,000 vs. 54,000). The anti-HA IgG1 and IgG2b antibody
responses were much higher in mice that were immunized with the
HAs vaccine in the presence of rOv-ASP-1 adjuvant than those
immunized in the absence of rOv-ASP-1 adjuvant (IgG1:
1,458,000 vs. 607,000 or 729,000; IgG2b: 243,000 vs. 162,000
or 54,000). All levels of IgG isotype responses in mice when the flu
vaccine was formulated with rOv-ASP-1 were statistically higher
than when mice were immunized with no adjuvant (p.0.05;
Fig. 3). There was no significant difference in the IgG1 and IgG2a
responses if the flu vaccine was given to naı ¨ve mice or to mice that
were previously immunized with another vaccine; rRBD of SARS-
CoV+rOv-ASP-1.
The rOv-ASP-1 as an adjuvant enhances humoral and
cellular responses in NHPs vaccinated with rRBD of SARS-
CoV
The adjuvanticity of rOv-ASP-1 was evaluated in a rhesus
macaque immunization model using rRBD as the target antigen of
Figure 3. Anti- HAs antibody responses in vaccinated mice.
Antibody responses to HAs in mice vaccinated previously with rRBD in
combination with the rOv-ASP-1 adjuvant were compared to those
generated in mice after primary immunization with the HA vaccine in
the presence or absence of the rOv-ASP-1 adjuvant. The IgG isotype
responses in individual mouse against influenza virus HAs from three
virus strains were tested by ELISA at 1:27,000 dilutions. * indicates
significant difference (p,0.05) among multiple comparisons; in
particular between mice that were immunized in the presence of rOv-
ASP-1 vs. no adjuvant.
doi:10.1371/journal.pone.0037019.g003
Table 2. Titers of anti-HA antibody response in rRBD+ rOv-
ASP-1 vaccinated mice and naı ¨ve mice after vaccination with
an influenza vaccine or an influenza vaccine in combination
with rOv-ASP-1.
End point titer 7 days post
boost
Vaccination group IgG1 IgG2a IgG2b
(RBD+rOv-ASP-1)+flu 607,500 486,000 162,000
(RBD+rOv-ASP-1)+(flu+rOv-ASP-1) 1,458,000 243,000 243,000
PBS+flu 729,000 486,000 54,000
PBS+(flu+rOv-ASP-1) 1,458,000 729,000 243,000
doi:10.1371/journal.pone.0037019.t002
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vaccinated with rRBD protein plus 50 mg (n=2), 100 mgr Ov-ASP-
1 (n=2) or 500 mg CpG (n=1) as the adjuvant developed RBD-
specific IgG antibody response with increasing antibody level after
each boost. RBD-specific antibodies were not detected in the pre-
immune sera of the vaccinated rhesus macaques or the rhesus
macaques injected with RBD+PBS control (n=1). Immunization
with rRBD plus an optimized quantity of the CpG (500 mg) as the
adjuvant as used in other vaccine studies [33,34] was the most
effective for the induction of RBD-specific antibodies, with
endpoint IgG titer of 102,400 after third boost.
Although this was a limited pilot experiment using only two
concentrations of the E. coli expressed rOv-ASP-1 adjuvant for the
formulation (50 mg, 100 mg), which was two or four times the
amount used in our mouse model experiments (25 mg), we clearly
show that immunization with 50 or 100 mg of the rOv-ASP-1
adjuvant exhibited a dose-dependent efficacy in the induction of
RBD-specific antibodies in the two macaques per group; endpoint
IgG titers of 3,200 (50 mg ) or 6,400 (100 mg). Notably, the anti-
rOv-ASP-1 antibody response titers to the adjuvant itself were
lower in the NHPs than we might have expected based on the data
in mice; the range in all the 4 immunized macaque monkeys was:
1:100–1:800 after first boost, 1:800–1:1,600 after second boost and
1:200–1;1600 after the third boost.
Although the anti-RBD endpoint tiers were much higher in the
NHP that was immunized with CpG, the differences in the NT50
titers were less prominent. Sera from all rhesus macaques
vaccinated with the rRBD+adjuvant formulation effectively
neutralized the infection of SARS pseudovirus in 293T cells
expressing the receptor ACE2 (ACE2/293T) with NT50 values of
1:3,500–1:6,392. As shown in Figure 4, sera from macaques
immunized with rRBD protein plus 100 mgr Ov-ASP-1 induced a
slightly higher titer of neutralizing antibody than the 50 mgr Ov-
ASP-1 group; 4,167/5,376 vs. 3,724/3,509. The macaques that
were immunized with CpG had a higher NT50 titer at 1:6,392.
In an in vitro study, as described above, we showed that mice
immunized with rRBD+rOv-ASP-1 had a strong cytokine produc-
tion ex vivo when stimulated with rRBD protein or RBD-specific
peptides N50 and N60. Notably, only a significant TNF-a
response was obtained in NHPs that were immunized with rRBD
in the presence of rOv-ASP-1 or CpG ex vivo when PBMCs were
stimulated with 5 mg/ml of rRBD (Table 4). The cytokine
response was similar regardless of the amount of rOv-ASP-1 used
as the adjuvant. All other secreted cytokines, such as IFN-c, IL-2,
IL-4, IL-5 and IL-6 were negligible.
Discussion
Vaccines remain the most effective means of preventing or
eradicating infectious diseases, and there are ongoing efforts to
apply active immunization approaches to prevent and treat
Table 3. RBD-specific IgG responses in NHPs immunized with rRBD in the presence of rOv-ASP-1 or CpG adjuvant.
Immunization Anti-RBD IgG titer
rRBD + 50 mg5 0 mg 100 mg 100 mg 500 mg
rOv-ASP-1 rOv-ASP-1 rOv-ASP-1 rOv-ASP-1 CpG PBS
Prebleed ,100 ,100 ,100 ,100 ,100 ,100
7 days post prime 400 ,100 400 ,100 ,100 ,100
7 days post 1st boost 800 200 1,600 6,400 6,400 ,100
7 days post 2nd boost 400 3,200 3,200 3,200 51,200 ,200
7 days post 3nd boost 3,200 3,200 6,400 6,400 102,400 200
doi:10.1371/journal.pone.0037019.t003
Figure 4. Neutralizing antibody titers induced in vaccinated
NHPs. Neutralizing antibody titers induced in NHPs immunized with
recombinant SARS-CoV RBD in the presence of 50 mg (N=2) or 100 mg
(N=2) of rOv-ASP-1 or 500 mg of the CpG adjuvant. Neutralizing
antibody titers against SARS pseudovirus using 293T/ACE cells were
determined in the presence of antisera from each of the RBD-
immunized NHPs. The data are presented as 50% neutralization titer
(NT50).
doi:10.1371/journal.pone.0037019.g004
Table 4. TNF-a response in immunized NHPs.
Immunization pg/ml
rRBD+PBS 152
rRBD+rOv-ASP-1 (50 mg) 1,056
rRBD+rOv-ASP-1 (50 mg) 1,292
rRBD+rOv-ASP-1 (100 mg) 1,350
rRBD+rOv-ASP-1 (100 mg) 771
rRBD+CpG (500 mg) 1,129
doi:10.1371/journal.pone.0037019.t004
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antigen-specific immune responses and can be a key element of
vaccine effectiveness [1,37,38].
Adjuvants can be broadly separated into two classes based on
their principal mechanism of action: vaccine delivery systems and
immunostimulation. Vaccine delivery systems are generally
particulate and function mainly to target associated antigens into
APCs, e.g., emulsions, microparticles, iscoms, and liposomes
[6,39]. Immunostimulatory adjuvants contain residues that are
recognized by receptors on APCs, such as TLRs, which play an
important role in the innate recognition of pathogens by DCs, and
thus directly activate innate immune responses. These adjuvants
are now regarded as the most effective means by which an
adjuvant-antigen complex can target APCs [40]. Adjuvants
targeting multiple innate immune receptors may prove to be the
most effective adjuvants, as they may induce different arms of the
immune responses in the host. A number of microbial products,
including bacterial LPS, peptidoglycan, dsRNA, muramyl pep-
tides, CpG, flagellin and microbial proteins, were shown to act as
vaccine adjuvants [41–45]. Some of these immunomodulators
could skew acquired immune responses towards a Th1-type
immune response. Adjuvants can also be classified according to
their capacity to stimulate either innate or adaptive immunity
based on significant differences in their cellular receptors and
mechanisms of action [46]. As previously noted, Alum is the only
adjuvant licensed in the U.S. for general use in humans. Yet, Alum
is not effective in stimulating Th1 and/or cytotoxic T cell
responses to a number of pathogens and is therefore limited in its
applications, in particular for new-generation vaccines [47]. Some
of the adjuvants being developed in clinical testing include MPL,
the saponin derivative QS-21, CpG, flagellin, and combinations of
some of these adjuvants [40–51].
One of the major concerns regarding the use of immunostimu-
latory adjuvants in humans is the possible increased risk of
autoimmune diseases due to targeting pattern recognition
receptors by such adjuvants. However, the recombinant Ov-ASP-
1 adjuvant we studied corresponds to a secreted filarial protein,
which is presented as an antigen in the O. volvulus exposed or
infected individuals in Africa. There is no evidence to show that
this secreted filarial protein could induce autoimmune disease in
the infected patients, thus excluding such a concern.
Polarized Th1-type immunity can be achieved by the addition
of complete Freund’s adjuvant and CpG DNA to an antigen [52–
54]. On the other hand, Th2 antibody responses can be induced
by the Alum or incomplete Freund’s adjuvant, as indicated by
increased IgG1 relative to IgG2a [53–55]. However, in situations
where both Th1 and Th2 responses are required for protection,
the choice of one regimen over another might be counter effective.
This has led to additional research for alternative adjuvants or
adjuvant combinations that promote balanced mixed Th1/Th2
responses. The present study clearly demonstrated that rOv-ASP-1
could effectively induce mixed RBD- or HA-specific Th1/Th2
antibody associated responses, when used as an adjuvant with
recombinant subunit vaccine or as an addition to a commercial
Flu vaccine (FLUVIRIN; using 20% of the dose recommended for
human use).
Since the rOv-ASP-1 adjuvant is a protein, it is potentially
processed and presented to the immune system and subsequently
induces antibodies against self. Therefore, concerns might be
raised whether preexisting anti-rOv-ASP-1 antibodies may sup-
press its adjuvanticity when it is used in subsequent vaccine
formulations. Previously we demonstrated that antibody response
to the adjuvant itself did not hindered the development of OVA,
rS or rRBD antigen-specific antibody responses after each boost;
in all cases the responses in the presence of rOv-ASP-1 were more
elevated than those in the presence of MPL+TMP or Alum
adjuvants. Our present results further confirmed that antibodies
induced against the adjuvant had no impact on its ability to induce
immune responses against bystander antigens when used as an
adjuvant in a sequential vaccine when two vaccine model systems
were used: the RBD of SARS-CoV spike protein and a
commercial influenza virus HA vaccine comprised of three virus
strains. Even though a high level of anti-rOv-ASP-1 antibodies
(1:256,000–1:512,000) was present in the sera of mice before the
administration of the second vaccine, the adjuvanticity of rOv-
ASP-1 was retained with efficacy similar to that obtained when it
was used as an adjuvant in a first vaccine immunization of naı ¨ve
mice (Table 2 and Figure 3); no difference in the IgG titers was
observed between the two vaccine groups, mice pre-immunized
with rRBD+rOv-ASP-1 or PBS. Thus, we confirmed that the
preexisting anti-rOv-ASP-1 antibodies induced by a previously
administrated rOv-ASP-1-based vaccine do not have a significant
effect on the adjuvanticity of rOv-ASP-1 when formulated in a
subsequent vaccine. Notably, immunization of NHPs with rOv-
ASP-1 did not induce high titers of anti-self-antibodies, for reasons
that are not yet clear. Future studies will be needed to further
validate that even these reasonably low antibody responses to the
adjuvant have no impact on subsequent use of this adjuvant with
other vaccines also in NHPs.
The pilot immunogenicity studies in the NHPs have provided us
with extremely valuable ‘‘Proof of Principal’’ information in an
outbred primate model. Firstly, no adverse reactions were
observed at the site of the immunizations, indicating the safety
of rOv-ASP-1 as an adjuvant. Secondly, using two concentration
of the rOv-ASP-1 adjuvant, 50 or 100 mg, and rRBD as the vaccine
antigen, we were able to induce after three immunizations high
titers of neutralizing antibodies (1:3,500–1:6,392) that much
exceed what is needed for protection against SARS-CoV infection
in vivo (.1:500) [56]. Moreover, our studies have shown that rOv-
ASP-1 was able to support the induction of functional antibodies
against a pathogen in NHPs, thus clearing the way for its future
development for human vaccines as well. Thus, this pilot NHP
study is a definitive step for demonstrating relevance of rOv-ASP-1
for human vaccine formulations, even though more studies will be
needed to find the optimized amount of the adjuvant in vaccine
formulations, which will specify the putative starting adjuvant dose
for future clinical trials of rOv-ASP-1-based vaccines. Interestingly,
we did not see augmented recall RBD specific cellular responses
except TNF-a ´. Therefore, future studies will be needed to validate
the adjuvanticity of rOv-ASP-1 in primates from the point of its
ability to augment the desired types of cellular responses are
associated with protective immunity against possibly other
pathogens, duration of immunity and the potential to establish T
cell memory. In summary, the present studies have advanced our
confidence that the rOv-ASP-1 protein adjuvant can be further
developed for human use, particularly when strong functional
balanced antibody responses are needed against the pathogens.
Importantly, the rOv-ASP-1 that was used to immunize mice
previously immunized with RBD+rOv-ASP-1 or the naı ¨ve mice
with the HA vaccine was expressed in the yeast. Having a
functional yeast expressed adjuvant will support future develop-
ment of a scalable process for the downstream manufacture of rOv-
ASP-1, including the development of a series of critical biochem-
ical and biophysical assays for in-process, release and stability
testing, which will result in a high-yield reproducible production
process and a stable product that is highly potent and stimulates
the desired antibody and cellular responses to co-administered
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Materials and Methods
Animals and Ethics Statement
Animal protocols were approved by the Institutional Animal
Care and Use Committee at the New York Blood Center (mice,
Protocols #255 and #194) and the Tulane National Primate
Research Center (NHPs, Protocol #P0052). The Tulane National
Primate Research Center TNPRC is a USDA-inspected and
Association for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC)-approved facility, and has
an Animal Welfare Assurance on file with the Office of Laboratory
Animal Welfare. All animal studies were carried out in strict
accordance with the recommendations of the American Veteri-
nary Medical Association (AVMA) Guidelines and the approved
protocols. The animals were handled delicately. Any treatment
was done with extreme care and professionalism to avoid any
unnecessary discomfort for the animals.
Forty- two female BALB/c mice aged 4–6 weeks and six
purpose-bred adult male Indian-origin rhesus macaques aged 6–
10 years were used in this study. Animal housing and environ-
mental conditions met all applicable standards. Blood was
collected retro-orbitally for mice and from the femoral vein using
the Sarstedt S-Monovette system for NHPs. The animals were
anesthetized using Ketamine (0.1 ml/kg IM), which ameliorate
any suffering of the animals during the blood draw or immuni-
zation. The NHP protocol also included a full CBC and Chem20
profile, which were taken at each blood drawing, with results
falling within normal levels. Their body weight was frequently
monitored and physical examinations were performed regularly by
the attending veterinarian.
Expression of the recombinant Ov-ASP-1 protein in E. coli
and yeast
The rOv-ASP-1 protein was expressed as a histidine-tagged
protein in Escherichia coli and purified as previously described [27].
The purified rOv-ASP-1 was tested negative in a Limulus
amoebocyte lysate assay. A quantitative LPS testing by Cambrex
BioScience showed that purified rOv-ASP-1 contained ,0.25
endotoxin units per milligram of the protein (25 pg endotoxin/
mg), and we considered it as an LPS-free stock.
In addition, we expressed rOv-ASP-1 in yeast. Yeast codon
optimized Ov-asp-1 cDNA sequence (AF020586) without the
region encoding the N-terminal signal peptide was cloned into
the Pichia expression vector pPICZaA (Invitrogen) using the EcoRI
and XbaI restriction sites. The recombinant plasmid was linearized
with SacI digestion and transformed into Pichia pastoris X33 strain
as described previously [57]. The positive transformants were
screened on Zeocin-resistant YPD plates, and the highest
expression clone was selected by scale up culturing. The
expression of rOv-ASP-1 with 66His and c-myc tag at C-terminus
was induced with 0.5% methanol and scaled up in 10 liters
fermentation as described previously [58].
The rOv-ASP-1 was purified from the fermentation culture with
SP Sepharose Fast Flow exchange chromatography as described
previously [58]. Briefly, the fermentation supernatant was filtered
through a 0.22 mm membrane and the pH was adjusted to 4.8 by
adding glacial acetic acid. The positively charged rOv-ASP-1 was
captured onto cation SP Sepharose FF column and eluted with
50 mM sodium acetate, pH 4.8 containing 200 mM NaCl. The
eluted rOv-ASP-1 pool was then purified and buffer exchanged
using gel filtration chromatography (Sephadex G-25 Fine) into
PBS, pH 7.2 [28,57]. The product was tested for its adjuvanticity
in mice using OVA as the model antigen as previously described
[27] and it was established that 100 mg yeast-expressed rOv-ASP-1
per mouse was as effective as 25 mg per mice of the E. coli
expressed rOv-ASP-1; both eliciting after two immunizations end
point anti-OVA IgG titers of 1:25,600 (data not shown). Thus, the
E. coli or the yeast expressed rOv-ASP-1 at their optimal quantities
can be used intermittently with assurance.
Immunization procedures in mice and NHPs
Mice were vaccinated subcutaneously with rRBD protein
purified from culture supernatant of transfected human embryonic
kidney cell-line 293T (HEK293T) (ATCC, VA) according to the
previously described protocol [31,59,60] using 20 mg/mouse of the
protein mixed in aqueous solution with the E. Coli-expressed
optimized quantity of rOv-ASP-1 (25 mg/mouse) in 200 ml. As
adjuvant controls we immunized mice with rRBD mixed with
Imject Alum (40 mg/mL Aluminum hydroxide+40 mg/mL mag-
nesium hydroxide, Thermo Scientific) diluted 1:1 with the vaccine
antigen in a total volume of 200 ml per mouse or with rRBD mixed
with 50 mg CpG-ODN1826 (InvivoGen, San Diego CA) in a total
volume of 200 ml per mouse. Mice immunized with rRBD in PBS
were used as the negative control. The mice were boosted twice 3
weeks apart with 10 mg/mouse of rRBD protein in PBS, rOv-ASP-
1, Imject Alum or CpG. All mice were bled retro-orbitally under
anaesthesia prior to immunizations and 10 days post injections.
Sera were stored at 280uC.
To test the adjuvanticity of rOv-ASP-1 in a sequential vaccine
model, we immunized intramuscularly naı ¨ve mice or mice that
were previously immunized with the rRBD+rOv-ASP-1 with a
commercial flu vaccine (100 ml/mouse) containing 3 mgo f
influenza virus hemagglutinin (HA) from each of the following 3
viruses: A/Brisbane/59/2007, IVR-148 (H1N1); A/Uruguay/
716/2007, NYMC X-175C (H3N2) (an A/Brisbane/10/2007-like
virus); and B/Brishbane/60/2008 (FLUVIRIN, Novartis). The
immunization was done in the presence or absence of the yeast-
expressed optimized quantity of rOv-ASP-1 (100 mg/mouse). The
mice were boosted once with the same dose of vaccines three
weeks later. All mice were bled prior to immunization and 7 days
post immunization as described above and sera were stored at
280uC.
Rhesus macaques were vaccinated subcutaneously with rRBD
protein (50 mg) with either 50 mg (n=2) or 100 mg (n=2) of E. coli-
expressed rOv-ASP-1, CpG-C-ISS-ODN C274 (500 mg; n=1)
(donated by Dynavax Technologies Corporation, Berkeley, CA) or
PBS (n=1). They were boosted with the same dose at 1-, 2- and 6-
month intervals. The macaques were bled before immunization
and 7 days post-immunization. Sera were collected for serological
testing, and PBMCs were purified for in vitro assays. A baseline
bleed was also provided.
Measurement of antigen-specific antibody responses
ELISA was used to detect specific antibody responses induced in
the vaccinated mouse or NHP. Briefly, 96-well micro titer plates
(Costar) were coated with rRBD (1 mg/ml), rOv-ASP-1 (1 mg/ml)
or HAs (2.5 mg/ml) at 4uC overnight. The plates were blocked
with 2% non-fat milk in PBS-Tween (0.05%) for 2 h at 37uC.
After washing the plates six times with PBS-T, serial diluted sera in
binding buffer (1% non-fat milk in PBS-T) were added into each
well in duplicate and incubated for 1 h at 37uC. Bound antibodies
were detected with HRP-conjugated goat anti-mouse IgG, IgG1,
IgG2a or IgG2b (Molecular Probes-Invitrogen) (1:2000 dilution)
or mouse anti-monkey IgG-HRP (clone SB108a, Southern
Biotech) (diluted 1:1000) in binding buffer. After incubation for
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added, and the reaction was stopped by the addition of 2 N
H2SO4. Absorbance at 450 nm was measured using SpectraMax
190 (Molecular Devices, Sunnyvale, CA). End point titers were
defined as the highest dilutions giving an A450 measurement of 0.1.
This cutoff value represents the value of mean optical density (OD)
plus 2 standard deviations (SD) of 10 normal mouse serum samples
tested at 1:100 dilutions or the 6 pre-bleeds from the normal NHP
serum samples also tested at 1:100 dilutions.
SARS pseudovirus neutralization assay
The neutralization assay against SARS pseudovirus infection
was performed as previously described [61]. In brief, plasmid
DNA encoding SARS-CoV spike protein and a plasmid DNA
encoding Env-defective, luciferase-expressing HIV-1 genome
(pNL4-3.luc.RE) were co-transfected into HEK293T cells (ATTC,
GA). Culture supernatant containing SARS pseudovirus was
collected at 72 h and used for single-cycle infection in vitro. The
SARS pseudovirus was incubated in the presence or absence of
serially diluted antisera from vaccinated mice or NHPs for 1 h at
37uC. Subsequently, the antisera-virus mixtures were added to
293T cells expressing the SARS receptor angiotensin-converting
enzyme 2 (293T/ACE2) in 96-well plates, and the infection was
allowed to proceed for 48 h, followed by lysing the infected cells
using cell lysis buffer included in the luciferase kit (Promega).
Aliquots of cell lysates were transferred to 96-well Costar flat-
bottom luminometer plates (Corning Costar), followed by addition
of luciferase substrate (Promega). Relative light units were
determined immediately in the Ultra 384 luminometer (Tecan).
The neutralization of SARS pseudovirus is presented as 50%
neutralizing antibody titer (NT50) [60].
Cytokine assays
Th1/Th2/Th17 cytokine assay was used to estimate the
corresponding cytokine production ex vivo from splenocytes of
the vaccinated mice. Briefly, splenocytes were harvested from the
immunized mice and resuspended in RPMI 1640 medium
(Invitrogen, Carlsbad, CA) supplemented with 10% FBS (Hyclone
Laboratories, Inc.), 2 mM L-glutamine, 10 mM HEPES, and
Antibiotic-Antimycotic (Invitrogen, Carlsbad, CA). The cells were
plated at 4610
5 cells into 96-well U-bottom culture plates for in
vitro stimulation with 5.0 mg of rRBD, or with the SARS-CoV
RBD-specific N50 (CD8
+ T cell epitope) or N60 (CD4
+ T cell
epitope) peptide [31]; a concentration that was pre-determined to
be optimal. Cells were stimulated with or without PMA (10 ng/ml)
plus ionomycin (1 mg/ml) as the positive and negative controls,
respectively. The plates were incubated at 37uC for 72 h, and the
secreted cytokines were quantified from the culture supernatants
using the Mouse Th1/Th2/Th17 BD Cytometric Bead Array Kit
(BD Biosciences) according to the manufacture’s protocols.
Theoretical limit of detection data is IL-2=0.1 pg/ml; IL-
4=0.03 pg/ml; IL-6=1.4 pg/ml; IL-10=16.8 pg/ml; TNF-
a=0.9 pg/ml, INF-c=0.5 pg/ml; and IL-17A=0.8 pg/ml.
Detection of the Th1/Th2 cytokine production in the
vaccinated NHPs was done using similar protocol as above with
some modifications. PBMCs were isolated following a Ficoll-
Hypaque density gradient (Sigma). Single-cell suspensions were
then stimulated at 4610
5 cells with 5 mg of rRBD, N50 or N60
peptides, or PMA (10 ng/ml) plus ionomycin (1 mg/ml) for
positive control and culture media alone for negative control.
The cells were stimulated for 5 days, and cytokines were quantified
using the Non-Human Primate Th1/Th2 BD Cytometric Bead
Array Kit (BD Biosciences) according to the manufacture’s
protocols.
Statistical analysis
Results are expressed as mean 6 SEM. The data were analyzed
using GraphPad version 5.01 for Windows (GraphPad software).
Unpaired two-tailed Student’s t test or Mann-Whitney test was
used to compare means between different groups. One-way
ANOVA with Bonferroni post-test was considered appropriate for
multiple comparisons. P value less than 0.05 was considered
significant.
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